Adverse drug reactions associated with first-line anti-tuberculosis drug regimens

International Journal of Tuberculosis and Lung Disease

Volumn 11, Issue 8, 2007, Pages 868-875

  Marra, F ^a,b   Marra, Carlo A ^a,c   Bruchet, N ^a   Richardson, K ^a,c   Moadebi, S ^b   Elwood, R K ^a,b   FitzGerald, J M ^a,d  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

^c Centre for Health Evaluation and Outcome Sciences   (Canada)

^d Centre for Clinical Epidemiology and Evaluation   (Canada)

Author keywords

Adverse events; First line medications; Tuberculosis

Indexed keywords

ASPARTATE AMINOTRANSFERASE; ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ABDOMINAL PAIN; ADULT; AGED; ANOREXIA; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; COMBINATION CHEMOTHERAPY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EVALUATION RESEARCH; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART PALPITATION; HEPATITIS; HUMAN; INCIDENCE; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTCOMES RESEARCH; PARESTHESIA; POPULATION RESEARCH; PRIMARY HEALTH CARE; PRIORITY JOURNAL; PRURITUS; RASH; RISK FACTOR; SIDE EFFECT; SWELLING; TINNITUS; TUBERCULOSIS; VERTIGO; VISUAL DISORDER; VOMITING; WEAKNESS; WEIGHT REDUCTION; ADVERSE DRUG REACTION;

ANTITUBERCULAR AGENTS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; ISONIAZID; PYRAZINAMIDE; RIFAMPIN; TUBERCULOSIS;

EID: 34547727687     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America. Treatment of Tuberculosis. Am J Respir Crit Care Med 2003; 167: 603-662.
2. Long R, ed. Canadian tuberculosis standards. 5th ed. Ottawa, Canada: Canadian Lung Assoc and Health, 2000.
3. Combs D L, O'Brien R J, Geiter L J. USPHS tuberculosis short-course chemotherapy trial 21: effectiveness, toxicity and acceptability: the report of final results. Ann Intern Med 1990; 112: 397-406.
4. Jindani A, Nunn A J, Enarson D A. Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomized trial. Lancet 2004; 364: 1244-1251.
5. Forget E J, Menzies D. Adverse reactions to first-line antituberculosis drugs. Expert Opin Drug Saf 2006; 5: 231-249.
6. Yee D, Valiquette C, Pelletier M, et al. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 2003; 167: 1472-1477.
7. Schaberg T, Rebhan K, Lode H. Risk factors for side effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur Respir J 1996; 9: 2026-2030.
8. Ungo J R, Jones D, Ashkin D, et al. Antituberculosis drug-induced hepatotoxicity: the role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med 1998; 157: 1871-1876.
9. Hwang S J, Wu J C, Lee C N, et al. A prospective clinical study of isoniazid-rifampicin-pyrazinamide-induced liver injury in an area endemic for hepatitis B. J Gastroenterol Hepatol 1997; 12: 87-91.
10. Essebag V, Platt R W, Abrahamowicz M, Pilote L. Comparison of nested case-control and survival analysis methodologies for analysis of time-dependent exposure. BMC Med Res Methodol 2005; 5: 5.
11. Marra F, Marra C A, Moadebi S, et al. Levofloxacin treatment of active tuberculosis and the risk of ADRs. Chest 2005; 128: 1406-1413.
12. Andersen P K, Gill R D. Cox's regression model counting process: a large sample study. Ann Stat 1982; 10: 1100-1120.
13. Lin D Y, Wei L J. The robust inference for the proportional hazards model. J Am Stat Assoc 1989; 84: 1074-1078.
14. Hosmer D W, Lemeshow S. Applied survival analysis: regression modeling of time to event data. New York, NY, USA: John Wiley, 1999.
15. Horsburgh C R Jr. Priorities for the treatment of latent tuberculosis infection in the United States. N Engl J Med 2004; 350: 2060-2067.
16. McDermott W, Ormond L, Muschenhein C, Deuschle K, McCune R M, Tompsett R. Pyrazinamide-isoniazid in tuberculosis. Am Rev Tuberc 1954; 69: 319-333.
17. Campagna M, Calix A A, Hauser G. Observations on the combined use of pyrazinamide (aldinamide) and isoniazid in the treatment of pulmonary tuberculosis. Am Rev Tuberc 1954; 69: 334-350.
18. Centers for Disease Control and Prevention. Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection - New York and Georgia 2000. MMWR Morb Mortal Wkly Rep 2001; 50: 289-291.
19. Wong W M, Wu P C, Yuen M F, et al. Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatology 2000; 31: 201-206.
20. Pan L, Jia Z S, Chen L, et al. Effect of anti-tuberculosis therapy on liver function of pulmonary tuberculosis patients infected with hepatitis B virus. World J Gastroenterol 2005; 11: 2518-2521.
21. Lee B H, Koh W J, Choi M S, et al. Inactive hepatitis B surface antigen carrier state and hepatotoxicity during anti-tuberculosis chemotherapy. Chest 2005; 127: 1304-1311.